Conference Coverage

Including quality-of-life scores may aid decision making for patients with advanced ovarian cancer


 

AT THE 2016 ASCO ANNUAL MEETING

References

“The health-related quality of life scores identified a subset of women with resistant/refractory disease who have a very poor prognosis. It’s more informative than a clinician-assigned ECOG performance status, and including baseline health-related quality of life together with clinical prognostic factors improved the prediction of survival in women with PRR-ROC,” Dr. Roncolato said, adding that having this additional prognostic information could improve stratification in clinical trials, patient-doctor communication about prognosis, and clinical decision-making.

This study was funded by the Australian National Health and Medical Research Council. Dr. Roncolato reported having no disclosures.

sworcester@frontlinemedcom.com

Pages

Recommended Reading

Olaparib benefit maintained long term
MDedge Hematology and Oncology
Neoadjuvant chemo for advanced ovarian cancer opens ‘window of opportunity’ for immunotherapies
MDedge Hematology and Oncology
Hormonal maintenance therapy prolonged PFS in LGSC
MDedge Hematology and Oncology
Statins improve ovarian cancer survival
MDedge Hematology and Oncology
MITO8: Re-treat with platinum-based chemo for recurrent OC
MDedge Hematology and Oncology
Metformin increases efficacy of everolimus-letrozole combo for EEC
MDedge Hematology and Oncology
Symptoms linger after ‘successful’ gyn. cancer therapy
MDedge Hematology and Oncology
In-person, telephone genetic counseling yield similar outcomes
MDedge Hematology and Oncology
Study links mismatch repair defects to lower PFS in endometrial cancer
MDedge Hematology and Oncology
FDA reports shortage of doxorubicin for injection, initiates importation
MDedge Hematology and Oncology